drugset / Trial / NCT05948826
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
Phase 1
Active not recruiting
70 enrolled
TORL Biotherapeutics, LLC
Translational Research in Oncology · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Timeline
- Start
- 2023-09-29
- Primary completion
- 2026-06-25
- Completion
- 2026-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TORL-3-600 | Other / unclassified | — | — |